Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

64.73
+0.28000.43%
Post-market: 64.730.00000.00%16:10 EDT
Volume:2.25M
Turnover:145.96M
Market Cap:12.51B
PE:170.80
High:65.67
Open:64.48
Low:64.34
Close:64.45
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.26
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.98
PE(LYR):35.96

Loading ...

Biomarin to Acquire Alesta Therapeutics to Gain Ale1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to Biomarin's Pipeline

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Deal Expected to be Modestly Dilutive to 2026 Financial Results

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Alesta Shareholders Eligible for up to $215 Mln in Milestone Payments

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - Alesta to Spin Out Non-Ale1 Assets and Employees Before Close

THOMSON REUTERS
·
Aug 18

Biomarin Pharmaceutical - to Fund Acquisition with Cash on Hand

THOMSON REUTERS
·
Aug 18

BioMarin Pharmaceutical is Maintained at Overweight by Piper Sandler

Dow Jones
·
Aug 18

BioMarin price target raised to $88 from $82 at Piper Sandler

TIPRANKS
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 17

U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies

Reuters
·
Aug 17

Biomarin Pharmaceutical Inc. : Piper Sandler Raises Target Price to $88 from $82

THOMSON REUTERS
·
Aug 17

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Simply Wall St.
·
Aug 17

BioMarin to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 10

Analysts Conflicted on These Healthcare Names: Evolent Health (EVH), Eli Lilly & Co (LLY) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 10

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 08

BioMarin price target raised to $86 from $80 at BofA

TIPRANKS
·
Aug 07

BioMarin Lifts 2026 Outlook on Strong Voxzogo Sales, Wedbush Says

MT Newswires Live
·
Aug 07

BioMarin price target raised to $124 from $119 at Morgan Stanley

TIPRANKS
·
Aug 07

Biomarin Pharmaceutical : Oppenheimer Raises Target Price to $97 from $95

THOMSON REUTERS
·
Aug 07

BioMarin Pharmaceutical Price Target Raised to $60.00/Share from $50.00 by HC Wainwright & Co.

Dow Jones
·
Aug 07

Morgan Stanley Adjusts PT on BioMarin Pharmaceutical to $124 From $119, Maintains Overweight Rating

MT Newswires Live
·
Aug 07